Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantSC
Saras Capital
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $46.4M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionConverge Bio
AI platform for accelerated drug discovery and development
$25MSeries A
Role not disclosedBiographica
Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience
£7MUndisclosed
Role not disclosed